Genmab A/S (GMAB) Expected to Announce Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Genmab A/S to post earnings of $0.47 per share and revenue of $975.4040 million for the quarter. Genmab A/S has set its FY 2025 guidance at EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Stock Up 0.2%

NASDAQ:GMAB opened at $28.76 on Wednesday. The stock’s 50 day moving average price is $29.37 and its 200 day moving average price is $24.30. The company has a market capitalization of $18.47 billion, a PE ratio of 14.45, a P/E/G ratio of 1.59 and a beta of 0.96. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $33.65.

Institutional Trading of Genmab A/S

Hedge funds have recently added to or reduced their stakes in the stock. Orbis Allan Gray Ltd lifted its holdings in shares of Genmab A/S by 38.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after buying an additional 2,209,659 shares during the period. Quantinno Capital Management LP grew its holdings in Genmab A/S by 64.9% during the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after acquiring an additional 62,226 shares during the period. Squarepoint Ops LLC grew its holdings in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after acquiring an additional 81,434 shares during the period. Sei Investments Co. grew its holdings in Genmab A/S by 4.2% during the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock worth $1,283,000 after acquiring an additional 2,496 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Genmab A/S during the second quarter worth $1,172,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Truist Financial raised their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Tuesday, September 23rd. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Finally, Wall Street Zen downgraded Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.